Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C

Internal Medicine

Volumn 47, Issue 14, 2008, Pages 1301-1307

  Arase, Yasuji ^a   Suzuki, Fumitaka ^a   Sezaki, Hitomi ^a   Suzuki, Yoshiyuki ^a   Kawamura, Yusuke ^a   Kobayashi, Masahiro ^a   Akuta, Norio ^a   Hosaka, Tetsuya ^a   Yatsuji, Hiromi ^a   Ikeda, Kenji ^a   Kobayashi, Mariko ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Chronic hepatitis C; Peginterferon; Ribavirin; Suitable treatment period

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALPHA2A;

ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY; TREATMENT DURATION; VIRUS LOAD; ADULT; BLOOD; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; FOLLOW UP; MALE; MIDDLE AGED; RECURRENT DISEASE; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECURRENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL;

EID: 53049101502     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.0797     Document Type: Article

References (22)

1. Schalm SW, Weiland O, Hansen BE, et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. Gastroenterology 117: 408-413, 1999.
2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965, 2001.
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982, 2002.
4. McHutchison JG, Manns M, Patel K, et al. International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123: 1061-1069, 2002.
5. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346-355, 2004.
6. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Antiviral Long-Term Treatment Against Cirrhosis Trial Group. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 26: 1015-1023, 2004.
7. Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 132: 103-112, 2007.
8. Jensen DM, Morgan TR, Marceltin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (49 kd)/ribavirin therapy. Hepatology 43: 954-960, 2006.
9. Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 131: 1040-1048, 2006.
10. Dalgard O, Bjøro K, Hellum KB, et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 40: 1260-1265, 2004.
11. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24/weeks in HCV genotype 2 or 3. N Engl J Med 352: 2609-2617, 2005.
12. Bruno S, Cammà C, Di Marco V, et al. Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol 41: 474-481, 2004.
13. Lindahl K, Stable L, Bruchfeld A, et al. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 41: 275-279, 2005.
14. von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129: 522-527, 2005.
15. Krawitt EL, Gordon SR, Grace ND, et al. for the New York New England Study Team. A study of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 101: 1268-1273, 2006.
16. Doglio A, Laffont C, Caroli-Bosc FX, Rochet P, Lefebvre J. Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant. J Clin Microbiol 37: 15617-1569, 1909.
17. Albadalejo J, Alonso R, Antinozzi R, et al. Multicenter evaluation of the COBAS AMPLICOR HCV assay, an integrated PCR system for rapid detection of hepatitis C virus RNA in the diagnostic laboratory. J Clin Microbiol 36: 862-865, 1998.
18. Dusheiko G, Schmilovitz-Weiss H, Brown D, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 19: 13-18, 1994.
19. Desmet VJ, Gerber M, Hoofnagle, JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19: 1513-1520, 1994.
20. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic, response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38: 645-652, 2003.
21. Ferenci P, Fried MW, Shiffinan ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 43: 425-433, 2005.
22. Iwasaki Y, Ikeda H, Araki Y, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 43: 54-63, 2006.